CRDF - Small Cap-Cardiff Oncology Outlines Data From Discontinued Colorectal Cancer Trial Stock Soars | Benzinga
Cardiff Oncology Inc (NASDAQ:CRDF) provided a clinical update on the first release of data from its ONSEMBLE trial of onvansertib in combination with FOLFIRI/bev in patients with second-line RAS-mutated metastatic colorectal cancer (mCRC).
Although the Phase 2 ONSEMBLE trial was discontinued as part of the company’s shift to a first-line mCRC program, it enrolled 23 patients randomized across three arms before closing the trial to new enrollment.
The 23 enrolled patients continued treatment per protocol. The clinical data repeats the efficacy findings of onvansertib in bev naïve patients seen in the company’s earlier Phase 1b/2 KRAS-mutated mCRC trial.
In August 2023, Cardiff Oncology discontinued enrollment in ...